Posts tagged ‘cancer research’
A unique population of microbes in the female breast may lay the groundwork for understanding how this bacterial community contributes to health and disease, according to a new study out of Western University (London, Canada). The study titled “Microbiota of human breast tissue,” is now published online, in advance of the May issue of Applied and Environmental Microbiology.
The human body is home to a large and diverse population of bacteria with properties that are both harmful and beneficial to our health. Studies are revealing the presence of bacteria in unexpected sites.
This new research has uncovered bacteria in breast tissue associated with cancer. Forms of bacteria known as ‘Proteobacteria’ were the most abundant, potentially as they are able to metabolize the fatty tissue, said the paper’s first author, Camilla Urbaniak, a PhD student in the Department of Microbiology & Immunology. Her studies, under the supervision of Lawson Health Research Institute Scientist and Schulich School of Medicine & Dentistry Professor Gregor Reid, involved breast tissue from 81 women in Canada and Ireland. Ten of the women undergoing breast reduction acted as controls, with 71 having benign or cancerous tumors. Bacteria were found in and beside the tumours.
“Although we have not proven that bacteria cause cancer, or that certain types of bacteria actually may reduce the risk of cancer, the findings open a completely new avenue for this important disease,” said Reid. “Imagine if women have a microbiota in the breast that puts them at higher risk of cancer? Or, if various drugs such as antibiotics or birth control pills alter the types of bacteria and their risk of cancer?”
Thanks to the University of Western Ontario for contributing this story.
Researchers at Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute have made a new discovery regarding how normal cells communicate and control their growth. The novel findings have the potential to better inform the selection of cancer drug therapies in clinical trials, and to improve drug resistance in cancer patients.
Published in the prestigious journal Nature today, researchers in Dr. Anthony Pawson’s lab at the Lunenfeld-Tanenbaum Research Institute studied a cell growth trigger that is initiated by a protein which is often mutated in cancer. This protein, called epithelial growth factor receptor (EGFR), sits on the cell surface, and sends signals inside cells to control processes such as cell survival and expansion. The protein is an important target for cancer drug therapies.
Using targeted mass spectrometry, a cutting-edge technology, scientists in Dr. Pawson’s lab tracked the assembly of multiple proteins into signaling complexes from the moment the EGFR signal is turned ‘on’, to when the cell signal turns ‘off’. In cancer, the ‘off’ signal is often defective, leading to uncontrolled cell growth.
Researchers have identified many genetic markers for familial breast cancers, but not for sporadic breast cancer, which accounts for 80 per cent of all cases. Sambasivarao Damaraju, a professor with the Faculty of Medicine & Dentistry and a researcher at the Cross Cancer Institute, worked with his team to scan the DNA of about 7,200 Alberta women, including those who have had sporadic breast cancer and those who have not had cancer. Their genomes were scanned from DNA isolated from blood.
The results? Women who had sporadic breast cancer frequently had a genetic marker on chromosome 4, a marker that has never been associated with familial breast cancer cases.
University of Montreal researchers have discovered a novel molecular mechanism that can potentially slow the progression of some cancers and other diseases of abnormal growth. In the May 23 edition of the prestigious journal Cell, scientists from the University of Montreal explain how they found that the anti-cancer and anti-proliferative drug rapamycin slows down or prevents cells from dividing.
“Cells normally monitor the availability of nutrients and will slow down or accelerate their growth and division accordingly. A key monitor of nutrients is a protein called the Target of Rapamycin (TOR), but we do not know the details of how this protein feeds signals downstream to control growth” says Dr. Stephen Michnick, senior author and a University of Montreal biochemistry professor. He adds that, “we were surprised to find that TOR hooks up to a circuit that controls the exit of cells from division which in turn modulates the RNA message that codes for a key cell cycle regulator called B-cyclin”.
Work by McMaster’s Mick Bhatia has been selected by the Canadian Cancer Society as part of the organization’s top 10 cancer research breakthroughs of 2012.